Canaccord analyst Whitney Ijem raised the firm’s price target on Taysha Gene Therapies to $7 from $6 and keeps a Buy rating on the shares. The firm said its 3Q23 earnings call included initial efficacy data in a 2nd Rett patient, and updated data from the first patient announced last quarter, both of which were positive.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TSHA:
- Taysha Gene Therapies price target lowered to $7 from $8 at Baird
- Taysha Gene Therapies reports Q3 EPS (93c), consensus (17c)
- Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
- Taysha Gene Therapies options imply 50.1% move in share price post-earnings
- TSHA Earnings Report this Week: Is It a Buy, Ahead of Earnings?